Aiming to transform cancer care by developing curative allogeneic cell therapies
PRESS RELEASES + EVENTS view all
Century Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
– Preclinical data supporting selection of CNTY-101 as lead product candidate presented at AACR Annual…
Century Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit
PHILADELPHIA, April 17, 2023 (GLOBE NEWSWIRE) — Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology…
We are building a fully integrated biotechnology company that is developing transformational next generation iPSC-derived iNK and iT cell therapies for hematological and solid tumor malignancies.
We are leveraging the unlimited self-renewing capacity of induced pluripotent stem cells (iPSC) and cutting-edge cellular engineering and manufacturing technologies to develop fit-for-purpose products with functionalities designed to overcome the limitations of existing cell therapies.